A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment

Dapagliflozin is a sodium–glucose co-transporter 2 inhibitor in development for the treatment of type 2 diabetes mellitus. A semi-mechanistic population pharmacokinetic (PK) model was developed for dapagliflozin and its inactive metabolite dapagliflozin 3-O-glucuronide (D3OG) with emphasis on renal...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Walt, J-S, Hong, Y, Zhang, L, Pfister, M, Boulton, D W, Karlsson, M O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674329/
https://www.ncbi.nlm.nih.gov/pubmed/23887724
http://dx.doi.org/10.1038/psp.2013.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674329/
https://www.ncbi.nlm.nih.gov/pubmed/23887724
http://dx.doi.org/10.1038/psp.2013.20

Ejemplares similares